A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-30

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, observer-blind, irrelevant comparator-controlled trial in male and female subjects ≥24 months of age and \<72 months of age. Subjects will be without symptomatic chronic cardiopulmonary disease, including recurrent wheezing. Subjects will be screened for seropositivity to RSV in a qualified serum microneutralization (MN) assay and will be excluded if titers for either RSV/A or RSV/B are \<1:16 (4 log2).

Treatments will comprise an IM dose of saline placebo or RSV F vaccine on Day 0 and an IM dose of RSV F vaccine or a licensed hepatitis A vaccine on Day 28. Hepatitis A vaccine (and in one group placebo) will be used to maintain the study blind; all subjects will receive a complete course of hepatitis A vaccine as a study benefit.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RSV-F Vaccine Dose Ranging Study in Young Women

NCT01704365

Respiratory Syncytial Virus (RSV)

COMPLETED PHASE2

A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults

NCT02298179

Respiratory Syncytial Virus (RSV)

COMPLETED PHASE1

A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization

NCT02624947

Respiratory Syncytial Virus Infections

COMPLETED PHASE3

Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children

NCT02601612

Respiratory Syncytial Virus Infections

COMPLETED PHASE1

Safety Study of Respiratory Syncytial Virus (RSV)-Fusion (F) Protein Particle Vaccine

NCT01290419

Respiratory Syncytial Virus Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Respiratory Synctial Virus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Group A

Day 0: RSV F Vaccine with adjuvant, Day 28: RSV F Vaccine with adjuvant

Group Type EXPERIMENTAL

RSV F Vaccine with adjuvant (0.5mL injection)

Intervention Type BIOLOGICAL

Treatment Group B

Day 0: RSV F Vaccine with adjuvant, Day 28: Hepatitis A Vaccine

Group Type EXPERIMENTAL

RSV F Vaccine with adjuvant (0.5mL injection)

Intervention Type BIOLOGICAL

Hepatitis A Vaccine (0.5mL injection)

Intervention Type BIOLOGICAL

Treatment Group C

Day 0: RSV F Vaccine, Day 28: RSV F Vaccine

Group Type EXPERIMENTAL

RSV F Vaccine (0.5mL injection)

Intervention Type BIOLOGICAL

Treatment Group D

Day 0: RSV F Vaccine, Day 28: Hepatitis A Vaccine

Group Type EXPERIMENTAL

RSV F Vaccine (0.5mL injection)

Intervention Type BIOLOGICAL

Hepatitis A Vaccine (0.5mL injection)

Intervention Type BIOLOGICAL

Treatment Group E

Day 0: Placebo, Day 28: Hepatitis A Vaccine

Group Type PLACEBO_COMPARATOR

Hepatitis A Vaccine (0.5mL injection)

Intervention Type BIOLOGICAL

Placebo (0.5mL injection)

Intervention Type BIOLOGICAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RSV F Vaccine with adjuvant (0.5mL injection)

Intervention Type BIOLOGICAL

RSV F Vaccine (0.5mL injection)

Intervention Type BIOLOGICAL

Hepatitis A Vaccine (0.5mL injection)

Intervention Type BIOLOGICAL

Placebo (0.5mL injection)

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy males and females, ≥24 months of age and \<72 months of age, without known chronic cardiopulmonary disease including especially persistent or frequently recurrent wheezing.
2. Free of other illnesses that are believed to increase the risks associated with influenza or other respiratory viral infections, including: diabetes mellitus, congenital or acquired blood dyscrasias, renal or hepatic dysfunction, and morbid obesity.
3. Parent(s)/guardian(s) willing and able to give informed consent prior to study enrollment, and assert ability to comply with study requirements.
4. Parent(s)/guardian(s) and/or other designated child care provider must have continuous capacity for telephone communication with the study site.

Exclusion Criteria

1. Serum MN titers against RSV/A or RSV/B \<1:16 (4 log2).
2. Toxicity grade ≥2 for any safety laboratory parameter.
3. Participation in research involving an investigational product (drug/biologic/device) within 45 days before planned date of first vaccination and planned participation at any time during the study.
4. History of a serious reaction to any prior vaccination, including Guillain-Barré Syndrome within six weeks following a previous influenza vaccination.
5. Receipt of any vaccine (other than the influenza vaccine specified in the protocol) in the four weeks preceding the first study vaccination and/or planned receipt of a licensed vaccine (other than the hepatitis A vaccine specified in the protocol) at any time prior to Study Day 56.
6. Receipt of an RSV vaccine at any time.
7. Any known or suspected immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination.
8. Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥1 mg/kg of prednisone per day or equivalent. The use of topical glucocorticoids for minor cutaneous symptoms will be permitted, but the use of nasal or inhaled glucocorticoids in exclusionary (because of potential related diagnoses rather than immunosuppression).
9. Administration of immunoglobulins and/or any blood products within the three months preceding the administration of the study vaccine or during the study.
10. Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever or an oral temperature \>38.0°C on the planned day of vaccine administration).
11. Known disturbance of coagulation.
12. Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including social, neurologic, or psychiatric conditions in the subject or parent(s)/guardian(s) deemed likely to impair the quality of safety reporting).

Minimum Eligible Age

24 Months

Maximum Eligible Age

72 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes